A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
← catalyst calendarNCT06339008 · readout ≤ 41 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
450estimated
Sites
74
Countries
Belgium, China, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-26 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Perennial Allergic Rhinitis (PAR)
Interventions
- Drug: LY3650150
- Drug: Placebo
- Drug: Standard therapy for INCS
Primary outcome
what the primary-completion date above is the date OFMean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at Week 16
measured Baseline, Week 16
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed